BiotechTube

Yondelis + Yondelis + Dexamethasone + Dexamethasone

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma, Leiomyosarcoma

Trial Timeline

May 1, 2003 → May 1, 2008

NCT ID
NCT00060944

About Yondelis + Yondelis + Dexamethasone + Dexamethasone

Yondelis + Yondelis + Dexamethasone + Dexamethasone is a phase 2 stage product being developed by Johnson & Johnson for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00060944. Target conditions include Liposarcoma, Leiomyosarcoma.

What happened to similar drugs?

0 of 1 similar drugs in Liposarcoma were approved

Approved (0) Terminated (0) Active (1)
🔄Abemaciclib + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00060944Phase 2Completed

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
44
efatutazoneDaiichi SankyoPhase 2
35
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
35
HDM201 + LEE011NovartisPhase 1
29
pazopanibNovartisPhase 2
35
PF-07220060 + MidazolamPfizerPhase 2
39
Sunitinib Malate (SU011248)PfizerPhase 2
35
CabazitaxelSanofiPhase 2
35
INCMGA00012 + PalbociclibIncytePhase 2
36
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
28
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
11